BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.
BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tisle...more >
|Stock Quote||more >|
12/14/18 4:00 p.m. ET
Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.
|Recent Press Releases||more >|
|BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress - December 10, 2018|
|CAMBRIDGE, Mass., and BEIJING, China, Dec. 10, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a c... Read More|
|BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - December 5, 2018|
|CAMBRIDGE, Mass. and BEIJING, China, Dec. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a co... Read More|